![Steven Powell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steven Powell
Directeur Général chez
Cambridge Cognition Ltd.
Fortune : 112 290 $ au 30/06/2026
Profil
Steven John Powell was the founder of Glen Clova Scientific Ltd., founded in 2022, where the title held was Executive Chairman from 2022 to 2026.
Dr. Powell is currently Chief Executive Officer & Director at Cambridge Cognition Ltd. Former jobs include CEO, Secretary & Head-Investors Relations at Plethora Solutions Holdings Plc from 2009 to 2011; Chief Executive Officer at K.S.
Biomedix Holdings Plc from 1999 to 2003; Chief Executive Officer at Plethora Solutions Plc; Chief Executive Officer at KS Biomedix Plc from 1999 to 2003; Chief Executive Officer at The Native Antigen Co., Ltd.; Chief Executive Officer at eTheRNA immunotherapies NV; Chief Executive Officer at Macrophage Pharma Ltd.; Non-Executive Chairman at Cambridge Cognition Holdings Plc from 2019 to 2026; Director at Gilde Investment Management BV; Director at Chroma Therapeutics Ltd. from 2009 to 2017; Non-Executive Director at Acacia Pharma Ltd.; Director at Macrotarg Ltd.; Principal at Radiometer A; Principal at Active Biotech AB; Partner at Gilde Healthcare Partners BV; Principal at Chiroscience Ltd.; Development Scientist at GSK International Ltd.; Principal at Whatman Ltd. (United Kingdom).
Education includes a doctorate from the University of Aberdeen and an undergraduate degree from The University of Wales.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2024 | 256 375 ( 0,55% ) | 112 290 $ | 30/06/2026 |
Postes actifs de Steven Powell
| Sociétés | Poste | Début |
|---|---|---|
Cambridge Cognition Ltd.
 Cambridge Cognition Ltd. Packaged SoftwareTechnology Services Engages in the creation, production and distribution of computer automated cognitive tests | Directeur Général | - |
Anciens postes connus de Steven Powell
| Sociétés | Poste | Fin |
|---|---|---|
| CAMBRIDGE COGNITION HOLDINGS PLC | Directeur Général | 23/05/2019 |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Directeur Général | 22/08/2022 |
The Native Antigen Co. Ltd.
 The Native Antigen Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Develops viral vectors technologies | Directeur Général | - |
Macrotarg Ltd.
 Macrotarg Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Directeur/Membre du Conseil | 16/06/2017 |
Formation de Steven Powell
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
32
Relations au 1er degré
21
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 21 |
|---|---|
Plethora Solutions Holdings Plc
 Plethora Solutions Holdings Plc Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for treatment and management of urological disorders | Health Technology |
Gilde Investment Management BV
 Gilde Investment Management BV Investment ManagersFinance GIM investment strategy focuses primarily on transactions involving business succession, buyouts and the growth of innovative firms. GIM provides their investee firms with access to their regional and international network of entrepreneurs, sector experts and advisors. The Gilde Buy Out Fund invests in mid-market private equity with a geographical focus on buyout transactions in Germany, Switzerland, Austria, France, Belgium and Luxembourg. They define mid-market as firms having an enterprise value between €75 and €600 million. They seek investment opportunities across all sectors in non-core businesses spun off from large multinationals, public-to-private transactions, secondary buyouts and family businesses. The Gilde Benelux fund targets only management buyouts of mid-market firms headquartered in the Benelux with transactions typically ranging between €15 and €75 million. They seek firms across all sectors with strong or niche market positions, sustainable cash flows, and growth opportunities through buy and build strategies and entrepreneurial management teams. The Gilde Healthcare fund focuses on private start-up firms in the healthcare sector. They seek primarily European and some US firms that develop new therapeutics, diagnostics and medical devices. They are active investment partners with involvement at board level. Portfolio risk is diversified across different development stages, varying business models, markets and geographies. Their preferred exit route is through IPOs within a realistic time-frame. | Finance |
Radiometer A/S
 Radiometer A/S Medical SpecialtiesHealth Technology Develops and manufactures blood gas instruments and support devices | Health Technology |
Whatman Ltd. (United Kingdom)
 Whatman Ltd. (United Kingdom) Industrial MachineryProducer Manufacturing Develops, manufactures, and markets separation technology used for filtration, purification and storage of chemicals, and other liquids and samples | Producer Manufacturing |
Active Biotech AB
 Active Biotech AB BiotechnologyHealth Technology Develops drugs for cancer, neurodegenerative and inflammatory diseases | Health Technology |
K.S. Biomedix Holdings Plc
 K.S. Biomedix Holdings Plc Pharmaceuticals: MajorHealth Technology Researches and develops biopharmaceutical products | Health Technology |
University of Aberdeen
 University of Aberdeen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cambridge Cognition Ltd.
Cambridge Cognition Ltd. Packaged SoftwareTechnology Services Engages in the creation, production and distribution of computer automated cognitive tests | Technology Services |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Engages in the discovery and development of therapies for the treatment of cancer and inflammation | Health Technology |
The University of Wales
 The University of Wales Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Plethora Solutions Plc | |
KS Biomedix Plc | |
Gilde Healthcare Partners BV
 Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners invests in lower middle market companies located in North America and Europe with an EBITDA of EUR 3 -20 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed, early, later, buyout and growth stage capital requirements with an investment size of EUR 50 million. It takes both minority and majority positions. | Finance |
Acacia Pharma Ltd.
 Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Provides supportive care product opportunities for post-surgical and cancer patients | Health Technology |
Macrotarg Ltd.
Macrotarg Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Health Technology |
The Native Antigen Co. Ltd.
The Native Antigen Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Develops viral vectors technologies | Commercial Services |
Chiroscience Ltd. | |
Cambridge Cognition Holdings Plc
 Cambridge Cognition Holdings Plc Packaged SoftwareTechnology Services Provides cognitive assessment software for clinical trials, academic research and healthcare provision | Technology Services |
GSK International Ltd.
 GSK International Ltd. Other Consumer ServicesConsumer Services Operates travel agency | Consumer Services |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Health Technology |
Macrophage Pharma Ltd.
 Macrophage Pharma Ltd. BiotechnologyHealth Technology Engages in research and experimental development on biotechnology | Health Technology |
